JP2013241442A5 - - Google Patents

Download PDF

Info

Publication number
JP2013241442A5
JP2013241442A5 JP2013154361A JP2013154361A JP2013241442A5 JP 2013241442 A5 JP2013241442 A5 JP 2013241442A5 JP 2013154361 A JP2013154361 A JP 2013154361A JP 2013154361 A JP2013154361 A JP 2013154361A JP 2013241442 A5 JP2013241442 A5 JP 2013241442A5
Authority
JP
Japan
Prior art keywords
pul130
pul128
pul131
cmv
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013154361A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013241442A (ja
JP6274770B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013241442A publication Critical patent/JP2013241442A/ja
Publication of JP2013241442A5 publication Critical patent/JP2013241442A5/ja
Application granted granted Critical
Publication of JP6274770B2 publication Critical patent/JP6274770B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013154361A 2006-06-07 2013-07-25 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体 Active JP6274770B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81168906P 2006-06-07 2006-06-07
US60/811,689 2006-06-07
US90254407P 2007-02-20 2007-02-20
US60/902,544 2007-02-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009514365A Division JP5822433B2 (ja) 2006-06-07 2007-06-06 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015247487A Division JP2016128418A (ja) 2006-06-07 2015-12-18 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体

Publications (3)

Publication Number Publication Date
JP2013241442A JP2013241442A (ja) 2013-12-05
JP2013241442A5 true JP2013241442A5 (https=) 2017-08-24
JP6274770B2 JP6274770B2 (ja) 2018-02-07

Family

ID=38832360

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009514365A Active JP5822433B2 (ja) 2006-06-07 2007-06-06 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体
JP2013154361A Active JP6274770B2 (ja) 2006-06-07 2013-07-25 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体
JP2015247487A Pending JP2016128418A (ja) 2006-06-07 2015-12-18 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009514365A Active JP5822433B2 (ja) 2006-06-07 2007-06-06 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015247487A Pending JP2016128418A (ja) 2006-06-07 2015-12-18 ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体

Country Status (5)

Country Link
US (5) US7704510B2 (https=)
EP (2) EP3031469B1 (https=)
JP (3) JP5822433B2 (https=)
CA (1) CA2654563A1 (https=)
WO (1) WO2007146024A2 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3031469B1 (en) 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
CA2682700A1 (en) * 2007-05-11 2008-11-20 Vakzine Projekt Management Gmbh Composition containing hcmv particles
US9439960B2 (en) 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production
AU2009223688B2 (en) * 2008-03-10 2014-12-11 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
AU2013202396B2 (en) * 2008-07-16 2014-07-10 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
PE20141435A1 (es) 2008-07-16 2014-10-22 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano
AU2012203417B2 (en) * 2008-07-16 2014-07-10 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
EP2303923B1 (en) * 2008-07-16 2015-06-24 Institute for Research in Biomedicine Human cytomegalovirus neutralising antibodies and use thereof
US8580276B2 (en) 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
WO2011057124A1 (en) * 2009-11-06 2011-05-12 Transtarget, Inc. Polyclonal bispecific antibody compositions and method of use
WO2011076883A1 (en) 2009-12-23 2011-06-30 4-Antibody Ag Binding members for human cytomegalovirus
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
HUE026646T2 (en) 2010-07-06 2016-07-28 Glaxosmithkline Biologicals Sa Preferred liposomes containing lipids of PKA value for delivery of RNA
PL2591114T3 (pl) 2010-07-06 2017-08-31 Glaxosmithkline Biologicals Sa Immunizacja dużych ssaków małymi dawkami rna
PT3970742T (pt) 2010-08-31 2022-06-27 Glaxosmithkline Biologicals Sa Lipossomas peguilados para entrega de arn codificador de imunogénio
US20130164289A1 (en) * 2010-09-09 2013-06-27 Virginia Commonwealth University Human cytomegalovirus vaccine
WO2012047732A2 (en) * 2010-09-29 2012-04-12 Genentech, Inc. Antibody compositions and methods of use
JP2013544504A (ja) * 2010-10-11 2013-12-19 ノバルティス アーゲー 抗原送達プラットフォーム
CA2825825A1 (en) * 2011-01-27 2012-08-02 The Trustees Of Princeton University Inhibitors of mtor kinase as anti-viral agents
WO2013006838A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
TWI570240B (zh) * 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
WO2013054199A2 (en) * 2011-10-12 2013-04-18 Novartis Ag Cmv antigens and uses thereof
KR20140138971A (ko) * 2012-03-28 2014-12-04 제넨테크, 인크. 항-hcmv 이디오타입 항체 및 이들의 용도
ES2753138T3 (es) 2012-07-06 2020-04-07 Glaxosmithkline Biologicals Sa Complejos de proteínas de citomegalovirus
DK2877580T3 (en) 2012-07-27 2019-04-23 Hope City VAT VACCINE TO DELIVER A UL128 COMPLEX AND PREVENT CMV INFECTION
EP2943221A1 (en) * 2013-01-10 2015-11-18 Novartis AG Influenza virus immunogenic compositions and uses thereof
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US20150322115A1 (en) * 2014-05-08 2015-11-12 Redvax Gmbh Means and methods for treating cmv
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
MA46584A (fr) 2016-10-21 2019-08-28 Modernatx Inc Vaccin contre le cytomégalovirus humain
US11572389B2 (en) * 2017-01-27 2023-02-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
CA3060019A1 (en) 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
KR20250006307A (ko) * 2017-09-13 2025-01-10 사노피 파스퇴르 인간 시토메갈로바이러스 면역원성 조성물
CN112512569A (zh) 2018-05-11 2021-03-16 希望之城 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途
CA3116175A1 (en) 2018-10-17 2020-04-23 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2020208082A1 (en) * 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cmv related diseases
KR102837045B1 (ko) 2020-06-09 2025-07-23 케이엠 바이올로직스 가부시키가이샤 사이토메갈로바이러스의 gB와 펜타머의 융합 단백질 및 당해 융합 단백질을 포함하는 백신
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
US20230293673A1 (en) * 2020-08-06 2023-09-21 La Jolla Institute For Immunology Methods for treating and preventing cytomegalovirus infection
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
TWI843471B (zh) * 2022-03-11 2024-05-21 財團法人國家衛生研究院 含抗原和dna之組成物及其用途
WO2025231404A1 (en) * 2024-05-03 2025-11-06 The Trustees Of Princeton University Telomerase inhibition for treating or inhibiting herpesvirus infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) * 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
AU2002247733B2 (en) * 2001-02-21 2007-12-13 The Wistar Institute Of Anatomy And Biology Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates
DE10232322A1 (de) * 2002-07-16 2004-07-29 Hahn, Gabriele, Dr. Viral kodierte CxC determinieren den Gewebetropismus von HCMV
EP3031469B1 (en) * 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
GB0700133D0 (en) * 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof

Similar Documents

Publication Publication Date Title
JP2013241442A5 (https=)
Ogembo et al. A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice
CN116333161B (zh) 一种covid-19亚单位疫苗及其制备方法与应用
CN105792842B (zh) 埃巴病毒疫苗
JP6535133B2 (ja) 新規のバキュロウイルスベクター及び使用の方法
CN105073196B (zh) 呼吸道合胞病毒f蛋白表位
Mulama et al. A multivalent Kaposi sarcoma-associated herpesvirus-like particle vaccine capable of eliciting high titers of neutralizing antibodies in immunized rabbits
IE60671B1 (en) Monoclonal antiobodies to HIV and related peptides
TW202202169A (zh) 預防嚴重急性呼吸症候群冠狀病毒第二型（ｓａｒｓ－ｃｏｖ－２）感染的生物可降解奈米複合物疫苗及方法
CN103476788A (zh) 免疫原性屈曲病毒肽
WO2015181142A1 (en) Cytomegalovirus complexes and uses thereof
US20230144060A1 (en) MERS-CoV VACCINE
KR20240137110A (ko) 오미크론 코로나바이러스 백신 구조체 및 이를 제조하고 사용하는 방법
Barasa et al. BALB/c mice immunized with a combination of virus-like particles incorporating Kaposi sarcoma-associated herpesvirus (KSHV) envelope glycoproteins gpK8. 1, gB, and gH/gL induced comparable serum neutralizing antibody activity to UV-inactivated KSHV
CN111996216A (zh) 腺相关病毒介导的新型冠状病毒抗体诱导物及疫苗组合物
WO2020186687A1 (zh) 一种特异性结合四种血清型登革病毒的人源抗体
WO2023111725A1 (en) Sars-cov-2 vaccines
US20230227848A1 (en) Coronavirus vaccine constructs and methods of making and using same
Shen et al. DNA vaccine prime and replicating vaccinia vaccine boost induce robust humoral and cellular immune responses against MERS-CoV in mice
CN116490204A (zh) 催化失活血管紧张素转换酶2(ace2)变体及其用途
WO2021178844A1 (en) Zika and flavivirus immunogenic compositions and their use
CN116847881A (zh) 经改良的冠状病毒疫苗
Earnest et al. Preclinical evaluation of a cross-protective ß-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59
CN100479858C (zh) 一种重组痘苗-sars疫苗及其制备方法
CN115975042B (zh) 一种β冠状病毒异源多聚体抗原、其制备方法和应用